Dr Diane Culik, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Diane Culik shares her Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Clare - England: Lyme Disease (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: I'd like to introduce Claire from England who has Lyme disease.

Welcome, Claire.  Could you tell us your story?  

Anthony - US: CVID (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Anthony from the United States shares his CVID and LDN story on the LDN Radio Show with Linda Elsegood.

LDN And Rheumatoid Arthritis

MITECHNEWS.COM
30 March 2021
https://mitechnews.com/guest-columns/ldn-and-rheumatoid-arthritis/

Reports from 23andme/CureTogether suggest that LDN (low dose naltrexone) is among the most effective and potent treatments for Rheumatoid Arthritis. Regular and consistent consumption of LDN significantly reduced the need to use other painkillers and disease modifying drugs among Rheumatoid Arthritis patients.
 

Nutrichem's LDN Book Event with Dr Adam Livingston (Low dose naltrexone) from LDN Research Trust on Vimeo.

Dr. Adam Livingston, PharmD, BSc., RPh.

Low-dose Naltrexone (LDN) Prescription Basics

Pharmacist Kent MacLeod at the LDN Book Event 2020 (Low dose naltrexone) from LDN Research Trust on Vimeo.

Kent MacLeod, RPh., B.Sc., Owner & CEO of NutriChem Compounding Pharmacy & Clinic

Low-dose Naltrexone (LDN) & The Gut Microbiome

Impact of Colchicine and Low-dose Naltrexone on COVID-19 (COLTREXONE)

HealthPartners institute
16 February 2021
https://clinicaltrials.gov/ct2/show/NCT04756128

Scientists Think They've Figured Out What's Triggering Brain Fog in COVID-19 Patients

MSN News Science Alert
11 February 2021
https://www.msn.com/en-us/news/technology/scientists-think-theyve-figured-out-whats-triggering-brain-fog-in-covid-19-patients/ar-BB1dBTTF?li=BBnbfcL

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Cancer Cell
16 January 2021
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00051-9

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Int Immunopharmacol
August 2018
https://pubmed.ncbi.nlm.nih.gov/29885638/